Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Original Article
M. Dougan, A. Nirula, M. Azizad, B. Mocherla, R.L. Gottlieb, P. Chen, C. Hebert, R. Perry, J. Boscia, B. Heller, J. Morris, C. Crystal, A. Igbinadolor, G. Huhn, J. Cardona, I. Shawa, P. Kumar, A.C. Adams, J.V. Naarden, K.L. Custer, M. Durante, G. Oakley, A.E. Schade, T.R. Holzer, P.J. Ebert, R.E. Higgs, N.L. Kallewaard, J. Sabo, D.R. Patel, M.C. Dabora, P. Klekotka, L. Shen, and D.M. Skovronsky
N Engl J Med 2021;385:1382-1392
Course summary
Available credit:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course opens:
10/06/2021
Course expires:
10/07/2023
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Saturday, October 7, 2023 - 11:59pm.

Facebook
X
LinkedIn
Forward